retatrutide type 2 diabetes phase 2 trial results 2024 ESC 2024: improves lipid and cardiovascular risk profile in II Effects of retatrutide, dulaglutide, and

of the human body (ref.4,9,10)

A Primer for Pharmacists (Part 2) CARDIOVASCULAR OUTCOME TRIALS IN DIABETES In late 2008, the United States (U.S.) Food and Drug Administration (FDA) published a Guidance for Industry that contained recommendations to be immediately adopted by pharmaceutical companies seeking approval for marketing new medications for the treatment of type 2 diabetes mellitus (T2DM)

Always consult your healthcare provider before starting these supplements

Reference: Paggers L, Mesotten D, Stragier H

Readings that previously averaged in diabetic or prediabetic ranges may shift 20-40 mg/dL lower

Fournel, A